Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Acute Pneumonia from Infections Acquired in Hospitals  – An Increasing Problem

Infections acquired in hospitals and nursing homes, such as hospital-acquired Pneumonia (HAP) and Ventilator Acquired Pneumonia (VAN), affect an estimated 10% of all hospitalized patients, causing pneumonia, urinary tract infections, wound infections or bloodstream infections. These infections can cause significant morbidity and mortality, and high economic burden to third-party payers and society. According to an estimate from the U.S. Centers for Disease Control and Prevention (CDC), infections acquired in hospitals cost more than $5 billion per year.

Patients with compromised immune systems, including the elderly and very young, are especially susceptible.  Hospital-acquired infections are transmitted through direct contact from hospital staff, patient-to-patient transmission, inadequately sterilized instruments, invasive interventions or even via the food or water provided at hospitals.  Most hospital-acquired infections are caused by bacteria, in particular by Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus species. It is estimated that more than 2 million hospital-acquired infections occur annually in the U.S. and about 1.2 million occur in Europe.  Moreover, the steady rise in antibiotic resistance within the last decade has dramatically increased the medical burden associated with hospital-acquired infections.

Patients in the Intensive Care Unit (ICU) contract hospital-acquired infections more frequently than those in the standard hospital ward and infections in the ICU are often caused by multidrug resistant (MDR) bacteria. The consequences of hospital-acquired infections in the ICU can range from an extended, costly stay in the ICU to life-threatening infection and death. Bloodstream infections and ventilator-associated pneumonia have particularly poor prognoses, with an associated mortality of up to 40%.

Current and Future Treatment of Hospital- Acquired Infections. The standard treatment for hospital-acquired infections is antibiotic therapy, many times given as a combination of up to three different drugs. However, the recent emergence of virulent, antibiotic-resistant bacteria has severely limited the effectiveness of modern antibiotics, leading to increased morbidity and mortality. Recent reports indicate that up to 60% of infections are resistant to the best antibiotics available. This is especially true for P. aeruginosa and S. aureus (e.g. Methicillin-resistant Staphylococcus aureus, MRSA).

As a consequence, the risk of death from a serious infection in an ICU setting has been estimated to be as high as 50%. In addition, the resulting prolonged ICU/hospital stay and additional medication and intensive care interventions can dramatically increase hospitalization costs. Thus, there is not only a very high medical need, but also an economic need for new anti-infective drugs.

Advantages of Monoclonal Antibody as an Anti-Infective

Combining mAb treatment with antibiotics can lead to more rapid resolution of infection, resulting in shorter stays in ICU and a significant reduction of morbidity, mortality and health care costs.

Antibodies are the workhorses of the human immune response, targeting and eliminating invading pathogens. The advantages to using therapeutic monoclonal antibodies, in addition to current therapy, are several fold:

The concept of combining monoclonal antibodies with standard-of-care antibiotics as a therapeutic approach has been emerging as a novel way to treat severe hospital-acquired infections.

With its fully human therapeutic antibodies, Aridis is well positioned to be a leader in this field.

Hospital-acquired Pneumonia

P. Aeruginosa Virus

Staphylococcus aureus Bacteria

Vancomycin-resistant Enterococcus


Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home